Kennett Sprogøe
Chief Tech/Sci/R&D Officer bij ASCENDIS PHARMA A/S
Vermogen: 436 579 $ op 31-03-2024
Oorsprong van het eerstegraads netwerk van Kennett Sprogøe
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 35 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Kennett Sprogøe via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| AMGEN INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| GILEAD SCIENCES, INC. | Biotechnology | Corporate Officer/Principal General Counsel | |
Frazier Management LLC
 Frazier Management LLC Investment ManagersFinance Frazier Management LLC (Frazier Healthcare Partners) is a venture capital subsidiary of Frazier & Co Inc. founded in 1991. The firm is headquartered in Seattle, Washington. | Investment Managers | Consultant / Advisor Private Equity Investor | |
Maxygen, Inc.
 Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| INTERMUNE INC | Biotechnology | Chief Tech/Sci/R&D Officer Director/Board Member | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Secretary Director of Finance/CFO Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| HUMANIGEN, INC. | Biotechnology | Sales & Marketing Chairman | |
Cellectricon AB
 Cellectricon AB Miscellaneous Commercial ServicesCommercial Services Cellectricon AB provides cell-based screening services to accelerate drug discovery. The firm develops and validates exciting central nervous system and peripheral pain assays using primary cells, accelerating the path from assay validation to compound screening. Its system is equipped with an imaging-based microplate reader to simultaneously record transient fluorescence and luminescence signals, providing real-time monitoring and readouts of cell culture response. The company was founded by Jan Owe Owesson Orwar, Daniel T. Chiu and Stig Anders Jakob Lindberg in 1999 and is headquartered in Molndal, Sweden. | Miscellaneous Commercial Services | Director/Board Member | |
| INTERCEPT PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chairman Corporate Officer/Principal | |
| VELOXIS PHARMACEUTICALS A/S | Pharmaceuticals: Major | Chief Executive Officer Director of Finance/CFO Chief Tech/Sci/R&D Officer Director of Finance/CFO Director of Finance/CFO | |
NextWave Pharmaceuticals, Inc.
 NextWave Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NextWave Pharmaceuticals, Inc. operates as a pharmaceutical company which focuses on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder. The company was founded by Mahendra G. Shah on September 25, 2006 and is headquartered in New York, NY. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Sofinnova Investments, Inc.
 Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | Investment Managers | Private Equity Investor Private Equity Investor | |
| GSK PLC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| Stanford University | College/University | Undergraduate Degree Masters Business Admin | |
| ALK-ABELLÓ A/S | Biotechnology | Corporate Officer/Principal Director/Board Member | |
| Copenhagen Business School | College/University | Graduate Degree Graduate Degree Graduate Degree Graduate Degree | |
| Technical University of Denmark | College/University | Doctorate Degree Doctorate Degree | |
| University of Copenhagen | College/University | Graduate Degree Graduate Degree Doctorate Degree Doctorate Degree | |
| University of Southern Denmark | College/University | Undergraduate Degree Doctorate Degree | |
Pharmaceutical Research & Manufacturers of America
 Pharmaceutical Research & Manufacturers of America Pharmaceuticals: MajorHealth Technology Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC. | Pharmaceuticals: Major | Director/Board Member | |
PricewaterhouseCoopers (Denmark)
 PricewaterhouseCoopers (Denmark) Miscellaneous Commercial ServicesCommercial Services Part of PricewaterhouseCoopers International Ltd., PricewaterhouseCoopers (Denmark) is a private company based in Hellerup, Denmark. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal Chairman | |
Symphogen A/S
 Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Major | Chief Executive Officer | |
MetaCure (USA), Inc.
 MetaCure (USA), Inc. Pharmaceuticals: MajorHealth Technology MetaCure (USA), Inc. engages in the development and commercialization of invasive treatment for diabetes. The company was founded by Shlomo Ben-Haim in 2003 and is headquartered in Orangeburg, NY. | Pharmaceuticals: Major | Director/Board Member | |
| ASCENDANT RESOURCES INC. | Other Metals/Minerals | Chief Executive Officer Chief Operating Officer | |
| BERGENBIO ASA | Pharmaceuticals: Major | Chief Executive Officer | |
| SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| Zealand Business College | College/University | Undergraduate Degree | |
Chempilots A/S
 Chempilots A/S Miscellaneous ManufacturingProducer Manufacturing Part of Biocoat, Inc., Chempilots A/S is a Danish company that specializes in developing and providing custom polymers using state-of-the-art technology. The private company is based in Farum, Denmark. The company offers a range of pre-specified products to signify their capabilities and give customers a starting point for selection. Chempilots specializes in poly(ortho esters) (poe), which belong to a class of degradable polymeric materials and were initially developed for drug delivery applications. Chempilots was acquired by Biocoat, Inc. on July 11, 2023. | Miscellaneous Manufacturing | Director/Board Member | |
| ACOUSORT AB | Medical Distributors | Chairman | |
| NUCANA PLC | Biotechnology | Director/Board Member Director/Board Member | |
| AUDENTES THERAPEUTICS, INC. | Biotechnology | Director/Board Member Chairman Director of Finance/CFO | |
| OBSEVA SA | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| SLS Invest ApS | Chief Investment Officer | ||
| KALVISTA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Nordic Eye Invest ApS
 Nordic Eye Invest ApS Investment ManagersFinance Nordic Eye Invest ApS (Nordic Eye) is an independent Danish venture capital firm which was founded in 2016. Nordic Eye is fully-owned by its partners, and has offices in Copenhagen, Denmark, and Los Angeles, California. | Investment Managers | Corporate Officer/Principal | |
Ascendis Pharma Endocrinology Division A/S
 Ascendis Pharma Endocrinology Division A/S Pharmaceuticals: MajorHealth Technology Ascendis Pharma Endocrinology Division A/S engages in pharmaceutical preparations. The company was founded on June 29, 2012 and is headquartered in Hellerup, Denmark. | Pharmaceuticals: Major | Chief Executive Officer Chairman | |
Nordic Eye Management ApS
 Nordic Eye Management ApS Financial ConglomeratesFinance Part of Nordic Eye Invest ApS, Nordic Eye Management ApS is an international venture capital firm based in Copenhagen, Denmark. The Danish company's brand promise is to spot, add, and exit, creating high value through a unique network, energetic and passionate collaboration, and an imaginative and commercial mindset. Nordic Eye has a strong personal network throughout the world, especially in the core markets. The CEO of the private company is Martin Olin. | Financial Conglomerates | Chief Executive Officer | |
VISEN Pharmaceuticals (Shanghai) Co., Ltd.
 VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| CESSATECH A/S | Pharmaceuticals: Major | Chairman Director/Board Member | |
| Ascendis Pharma Bone Diseases A/S | Chief Executive Officer Chairman | ||
| Ascendis Pharma Growth Disorders AS | Chief Executive Officer Chairman | ||
VISEN Pharmaceuticals
 VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China. | Biotechnology | Director/Board Member Chairman |
Statistieken
Internationaal
| Denemarken | 22 |
| Verenigde Staten | 16 |
| Zweden | 5 |
| Verenigd Koninkrijk | 3 |
| Zwitserland | 3 |
Sectoraal
| Health Technology | 28 |
| Finance | 7 |
| Consumer Services | 7 |
| Commercial Services | 4 |
| Electronic Technology | 2 |
Operationeel
| Director/Board Member | 198 |
| Corporate Officer/Principal | 89 |
| Independent Dir/Board Member | 62 |
| Chairman | 59 |
| Chief Executive Officer | 29 |
Sterkste connecties
| Insiders | |
|---|---|
| James Healy | 50 |
| Jonathan Silverstein | 42 |
| Albert Cha | 30 |
| Lars Holtug | 26 |
| Martin Olin | 25 |
| Rafaèle Elisabeth Tordjman | 23 |
| Michael Wolff Jensen | 23 |
| Mark Brennan | 21 |
| William Fairey | 15 |
| Jonathan Leff | 14 |
| Edwin de Graaf | 14 |
| Birgitte Volck | 13 |
| Lisa Bright | 13 |
| Jan Mikkelsen | 13 |
| Jesper Høiland | 12 |
- Beurs
- Insiders
- Kennett Sprogøe
- Bedrijfsconnecties
